[144] Protagonist Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Protagonist Therapeutics, Inc. (PTGX) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $248,800 and an approximate sale date of 09/22/2025 on NASDAQ. The filer acquired the shares on 05/03/2022 via previously exercised stock options and paid cash. The filing also discloses a 10b5-1 sale by the same person of 4,000 shares on 08/27/2025 for gross proceeds of $237,000. The notice includes the seller’s representation about absence of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider notice of proposed sale; transaction size is modest relative to typical market caps.

The Form 144 documents an insider-originated sale plan: 4,000 shares to be sold with an aggregate market value of $248,800 and prior 10b5-1 sales of 4,000 shares generating $237,000. The shares were acquired via exercised options in May 2022 and paid in cash, indicating routine liquidity by an insider rather than company-originated dilution. No new earnings, financings, or governance changes are disclosed.

Compliance/Risk Analyst

TL;DR: Filing appears compliant with Rule 144 and notes 10b5-1 activity; no material adverse information asserted.

The notice includes the required representation that the seller is unaware of undisclosed material adverse information and references reliance on a 10b5-1 plan for recent sales. Dates of acquisition and payment are provided, and the broker is identified. There are no indications of regulatory exceptions or unusual payment arrangements in the disclosed details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4000	248800.00	62211318	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/03/2022	Previously Exercised Stock Options	Issuer			4000	05/03/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for WILLIAM D WADDILL 7707 Gateway Boulevard, Suite 140 Newark CA 94560	Common	08/27/2025	4000	237000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for PTGX report?

The Form 144 reports a proposed sale of 4,000 common shares with an aggregate market value of $248,800 and an approximate sale date of 09/22/2025.

How were the shares being sold by the PTGX insider acquired?

The shares were acquired on 05/03/2022 through previously exercised stock options and payment was made in cash.

Was there any recent sale by the same person reported?

Yes, a 10b5-1 sale of 4,000 shares on 08/27/2025 generating gross proceeds of $237,000 is disclosed.

Which broker is handling the proposed sale in the PTGX filing?

The listed broker is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York NY 10004.

Does the filer assert any undisclosed material information about PTGX?

By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.